Metabolic Syndrome in Psoriasis and Psoriatic Arthritis in a Mixed Race Population: Comparison of Their Prevalences.

IF 5.2 Q1 DERMATOLOGY Psoriasis (Auckland, N.Z.) Pub Date : 2024-10-31 eCollection Date: 2024-01-01 DOI:10.2147/PTT.S471707

Patrícia Medeiros Gusmão Acioly, Mara Diane Lisboa Tavares Mazzillo, Carla Jorge Machado, Cláudia Camargo, Maria Alice Penetra, Virginia Januário, Beatriz Ribeiro Dos Reis, Marcia Ramos-E-Silva, Sueli Carneiro

{"title":"Metabolic Syndrome in Psoriasis and Psoriatic Arthritis in a Mixed Race Population: Comparison of Their Prevalences.","authors":"Patrícia Medeiros Gusmão Acioly, Mara Diane Lisboa Tavares Mazzillo, Carla Jorge Machado, Cláudia Camargo, Maria Alice Penetra, Virginia Januário, Beatriz Ribeiro Dos Reis, Marcia Ramos-E-Silva, Sueli Carneiro","doi":"10.2147/PTT.S471707","DOIUrl":null,"url":null,"abstract":"Background: There is a growing body of evidence suggesting the association between psoriasis (PsO) and psoriatic arthritis (PsA) separately with metabolic syndrome (MS) in different populations. The literature is relatively scarce in terms of comparing the prevalence of MS in PsO and PsA with controls without systemic inflammatory diseases.Objective: We aimed to assess the prevalence of MS among patients with PsO, PsA, and a control group without systemic inflammatory disease, in addition to investigating the risks of MS occurrence and its different components in each group.Methods: This is a cross-sectional case-control study with three groups of patients: PsO, PsA, and control. The diagnosis of MS was defined according to the modified 2009 NCTEP ATP III criteria. Patients underwent thorough physical examination and fasting blood samples.Results: A total of 195 patients were included in this analysis (PsO = 50; PsA = 64, and controls = 81). The prevalence of MS in the control, PsO, and PsA groups was 37%, 56%, and 57.8%, respectively (p < 0.001). Waist circumference (p = 0.013) and arterial hypertension (p < 0.001) were the most significant components of MS in patients with PsO and PsA. Multivariate analysis confirmed an independent risk of MS in women, elderly patients, obese patients, patients with hyperglycemia, and patients with psoriasis, especially PsA (OR = 6.2 [CI 95% 2.4-16.2], p < 0.001).Conclusion: MS is more prevalent in patients with PsA, which can be determined by the increase in inflammatory pathways.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"14 ","pages":"123-130"},"PeriodicalIF":5.2000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533878/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psoriasis (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PTT.S471707","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is a growing body of evidence suggesting the association between psoriasis (PsO) and psoriatic arthritis (PsA) separately with metabolic syndrome (MS) in different populations. The literature is relatively scarce in terms of comparing the prevalence of MS in PsO and PsA with controls without systemic inflammatory diseases.

Objective: We aimed to assess the prevalence of MS among patients with PsO, PsA, and a control group without systemic inflammatory disease, in addition to investigating the risks of MS occurrence and its different components in each group.

Methods: This is a cross-sectional case-control study with three groups of patients: PsO, PsA, and control. The diagnosis of MS was defined according to the modified 2009 NCTEP ATP III criteria. Patients underwent thorough physical examination and fasting blood samples.

Results: A total of 195 patients were included in this analysis (PsO = 50; PsA = 64, and controls = 81). The prevalence of MS in the control, PsO, and PsA groups was 37%, 56%, and 57.8%, respectively (p < 0.001). Waist circumference (p = 0.013) and arterial hypertension (p < 0.001) were the most significant components of MS in patients with PsO and PsA. Multivariate analysis confirmed an independent risk of MS in women, elderly patients, obese patients, patients with hyperglycemia, and patients with psoriasis, especially PsA (OR = 6.2 [CI 95% 2.4-16.2], p < 0.001).

Conclusion: MS is more prevalent in patients with PsA, which can be determined by the increase in inflammatory pathways.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

混血人群中银屑病和银屑病关节炎的代谢综合征：两者患病率的比较。

背景：越来越多的证据表明，在不同人群中，银屑病（PsO）和银屑病关节炎（PsA）分别与代谢综合征（MS）有关。在比较银屑病和银屑病关节炎与无系统性炎症性疾病的对照组的 MS 患病率方面，文献相对较少：我们的目的是评估 PsO、PsA 患者和无系统性炎症性疾病对照组中 MS 的患病率，同时调查每组中 MS 发生的风险及其不同组成部分：这是一项横断面病例对照研究，包括三组患者：方法：这是一项横断面病例对照研究，包括三组患者：PsO、PsA 和对照组。多发性硬化症的诊断根据 2009 年修订的 NCTEP ATP III 标准确定。患者接受了全面的身体检查和空腹血样采集：本次分析共纳入 195 例患者（PsO = 50 例；PsA = 64 例；对照组 = 81 例）。对照组、PsO 组和 PsA 组的 MS 患病率分别为 37%、56% 和 57.8%（p < 0.001）。腰围（p = 0.013）和动脉高血压（p < 0.001）是 PsO 和 PsA 患者 MS 的最重要组成部分。多变量分析证实，女性、老年患者、肥胖患者、高血糖患者和银屑病患者（尤其是 PsA 患者）有发生 MS 的独立风险（OR = 6.2 [CI 95% 2.4-16.2]，p < 0.001）：结论：多发性硬化症在 PsA 患者中发病率较高，这可以通过炎症途径的增加来确定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Psoriasis (Auckland, N.Z.)

自引率

0.00%

发文量

审稿时长

16 weeks